Vandetanib (ZD6474) (Synonyms: ZD6474) |
| Catalog No.GC15022 |
Vandetanib (ZD6474) (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib (ZD6474) also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 443913-73-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ZD6474 is a dual inhibitor of VEGFR-2 and EGFR with IC50 values of 40 nM and 500 nM, respectively [1].
ZD6474 showed potent inhibition activities against recombinant VEGFR-2 and EGFR in the in vitro assays. The inhibition of VEGFR-2 was 2.7-fold more potent than that of VEGFR-3 (Flt-4) kinase and 40-fold more potent than that of VEGFR-1. In human umbilical vein endothelial cells, treatment of ZD6474 resulted in significant inhibition of cell proliferation stimulated by VEGF and EGF with IC50 values of 60 and 170 nM, respectively. Through inhibiting the kinase activity of EGFR, ZD6474 can inhibit cell growth of various cancer cell lines, including lung, ovarian, breast and colon cancers. Besides that, ZD6474 administration inhibited tumor growth in a dose-dependent manner in many tumor xenograft models.
References:
[1] Ryan A J, Wedge S R. ZD6474–a novel inhibitor of VEGFR and EGFR tyrosine kinase activity[J]. British journal of cancer, 2005, 92: S6-S13.
| Cell experiment: [1] | |
|
Cell lines |
TT and MZ-CRC-1 cells |
|
Preparation method |
The solubility of this compound in DMSO is <10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
250 nM, 5 days for TT cells 6 days for MZ-CRC-1 cells |
|
Applications |
After 5 days of treatment, TT (harboring RET/C634W) cells treated with vehicle numbered 1300×103 and those treated with 250 nM ZD6474 numbered 800×103. MZ-CRC-1 (harboring RET/M918T) cells treated (for 6 days) with vehicle or 250 nM ZD6474 numbered 1144×103 and 712×103 respectively. In TT cells, ZD6474 exerted modest cytotoxicity at doses in the range of its IC50 for the RET kinase. A trypan blue exclusion viability assay confirmed that the compound exerted, instead, cytotoxicity at 1 week of treatment at doses of 1–5 μM. |
| Animal experiment: [2] | |
|
Animal models |
Female BALB/c-nu/nu athymic mice injected with TKKK-Luc and OZ-Luc cells |
|
Dosage form |
Oral administration; 50, 25, or 12.5mg/kg; daily |
|
Applications |
Mice were randomly divided into four treatment groups, namely vandetanib 50, 25, or 12.5mg/kg per b.w. per day, or vehicle control. Treatment started from the next day and continued for at least 4 weeks. The growth of the TKKK-Luc xenograft was significantly suppressed by vandetanib treatment at a lower dose, 12.5–25 mg/kg, whereas reduction of the OZ-Luc xenograft tumor was observed at a vandetanib dose of 50 mg/kg. At the end of the study, tumor volume was significantly lower in the vandetanib 50 mg/kg group of the OZ-Luc xenograft and in the 12.5–50 mg/kg group of the TKKK-Luc xenograft than in the vehicle-treated control group. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine-related cancer, 2011, 18(1): 1-11. [2] Yoshikawa D, Ojima H, Kokubu A, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. British journal of cancer, 2009, 100(8): 1257-1266. | |
| Cas No. | 443913-73-3 | SDF | |
| Synonyms | ZD6474 | ||
| Chemical Name | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine | ||
| Canonical SMILES | CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC | ||
| Formula | C22H24BrFN4O2 | M.Wt | 475.35 |
| Solubility | ≥ 11.9mg/mL in DMSO with gentle warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1037 mL | 10.5186 mL | 21.0371 mL |
| 5 mM | 0.4207 mL | 2.1037 mL | 4.2074 mL |
| 10 mM | 0.2104 mL | 1.0519 mL | 2.1037 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *